Federal Register / Vol. 82, No. 166 / Tuesday, August 29, 2017 / Notices 41053 

1 Vice Chairman Johanson and Commissioner 

Broadbent voted to conduct a full review of the 

order. Chairman Schmidtlein and Commissioner 

Williamson voted to conduct an expedited review 

of the order. 

(approximately $500); for a total of 

$138,188. We have not identified any 

other non-hour cost burdens associated 

with this collection of information. 

Abstract: This notice concerns the 

paperwork requirements of 30 CFR 250, 

Subpart M, Unitization, and related 

documents. The BSEE must approve any 

lessee’s proposal to enter an agreement 

to unitize operations under two or more 

leases and for modifications when 

warranted. We use the information to 

ensure that operations under the 

proposed unit agreement will result in 

preventing waste, conserving natural 

resources, and protecting correlative 

rights including the government’s 

interests. 

The authorities for this action are the 

Outer Continental Shelf Lands Act 

(OCSLA, 43 U.S.C. 1334), the Federal 

Oil and Gas Royalty Management Act 

(FOGRMA, 30 U.S.C. 1751), the 

Independent Offices Appropriations Act 

(IOAA, 31 U.S.C. 9701), and the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 3501, et seq.). 

Dated: July 21, 2017. 

Doug Morris, 

Chief, Office of Offshore Regulatory Programs. 

[FR Doc. 2017–18264 Filed 8–28–17; 8:45 am] 

BILLING CODE 4310–VH–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 731–TA–891 (Third 

Review)] 

Foundry Coke From China: Notice of 

Commission Determination To 

Conduct a Full Five-Year Review 

AGENCY: United States International 

Trade Commission. 

ACTION: Notice. 

SUMMARY: The Commission hereby gives 

notice that it will proceed with a full 

review pursuant to the Tariff Act of 

1930 to determine whether revocation of 

the antidumping duty order on foundry 

coke from China would be likely to lead 

to continuation or recurrence of material 

injury within a reasonably foreseeable 

time. A schedule for the review will be 

established and announced at a later 

date. 

DATES: August 4, 2017. 

FOR FURTHER INFORMATION CONTACT: Abu 

B. Kanu (202–205–2597), Office of 

Investigations, U.S. International Trade 

Commission, 500 E Street SW., 

Washington, DC 20436. Hearingimpaired persons can obtain 

information on this matter by contacting 

the Commission’s TDD terminal on 202– 

205–1810. Persons with mobility 

impairments who will need special 

assistance in gaining access to the 

Commission should contact the Office 

of the Secretary at 202–205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its internet server (https://

www.usitc.gov). The public record for 

this review may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. 

For further information concerning 

the conduct of this review and rules of 

general application, consult the 

Commission’s Rules of Practice and 

Procedure, part 201, subparts A through 

E (19 CFR part 201), and part 207, 

subparts A, D, E, and F (19 CFR part 

207). 

SUPPLEMENTARY INFORMATION: On August 

4, 2017, the Commission determined 

that it would proceed to a full review in 

the subject five-year review pursuant to 

section 751(c) of the Tariff Act of 1930 

(19 U.S.C. 1675(c)). In response to the 

Commission’s notice of institution (82 

FR 20381, May 1, 2017), the 

Commission found that the domestic 

interested party group response was 

adequate and the respondent interested 

party group response was inadequate. 

The Commission also found that other 

circumstances warranted conducting a 

full review.1 A record of the 

Commissioners’ votes, the 

Commission’s statement on adequacy, 

and any individual Commissioner’s 

statements will be available from the 

Office of the Secretary and at the 

Commission’s Web site. 

Authority: This review is being conducted 

under authority of title VII of the Tariff Act 

of 1930; this notice is published pursuant to 

section 207.62 of the Commission’s rules. 

By order of the Commission. 

Issued: August 23, 2017. 

Katherine M. Hiner, 

Supervisory Attorney. 

[FR Doc. 2017–18227 Filed 8–28–17; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Fresenius Kabi USA, LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before September 28, 2017. Such 

persons may also file a written request 

for a hearing on the application 

pursuant to 21 CFR 1301.43 on or before 

September 28, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on June 5, 

2017, Fresenius Kabi USA, LLC, 3159 

Staley Road, Grand Island, New York 

14072 applied to be registered as an 

importer of remifentanil (9739), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance for product 

development and preparation of 

stability batches. 

Dated: August 21, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–18312 Filed 8–28–17; 8:45 am] 

BILLING CODE 4410–09–P 


sradovich on DSK3GMQ082PROD with NOTICES